DOVONEX CREAM

Compare DOVONEX CREAM  to:
Compare
Compare

Generic Name for DOVONEX CREAM

Calcipotriene (as monohydrate) 0.005%.

Legal Classification:

Rx

Pharmacological Class for DOVONEX CREAM

Vitamin D3 derivative.

Manufacturer of DOVONEX CREAM

LEO Pharma Inc.

Indications for DOVONEX CREAM

Plaque psoriasis.

Adult dose for DOVONEX CREAM

Apply a thin layer twice daily to affected skin and gently rub in completely.

Children's dosing for DOVONEX CREAM

Not recommended.

Also:

Contraindications for DOVONEX CREAM

Hypercalcemia. Vit. D toxicity. Do not use on face. Scalp soln: acute psoriatic eruptions.

Warnings/Precautions for DOVONEX CREAM

For dermatologic use only. Avoid mucous membranes. Discontinue if irritation or hypercalcemia occurs (until normocalcemia returns). Elderly. Pregnancy (Cat.C). Nursing mothers.

Adverse Reactions for DOVONEX CREAM

Local irritation, burning/stinging, pruritus, dermatitis, worsening of psoriasis.

How is DOVONEX CREAM supplied?

Crm—60g, 120g
Soln—60mL

Related Disease:

Plaque psoriasis
Psoriasis~antipsoriatics

Related Resources

Oxsoralen-Ultra available again

June 23, 2010

Valeant Pharmaceuticals announced that it's Oxsoralen-Ultra (methoxsalen capsules) is available again for the treatment of severe psoriasis.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

Restylane-L and Perlane-L dermal fillers approved

February 03, 2010

The FDA has approved Medicis' hyaluronic acid with lidocaine dermal fillers, Restylane-L and Perlane-L.

Juvéderm XC dermal filler approved

February 02, 2010

The FDA has approved Juvéderm XC (hyaluronic acid and lidocaine [preservative-free] injectable gel, from Allergan) dermal filler for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (eg, nasolabial folds).

Phase 2b study of apremilast for treatment of plaque-type psoriasis

December 16, 2009

Celgene announced clinical data from its Phase 2b study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions